Epilepsy Surgery Market Highlights

The Epilepsy Surgery Market is witnessing notable advancements in the field of brain surgery for seizures, offering new hope for individuals with medically refractory epilepsy. Brain surgery for seizures, also known as epilepsy surgery, involves the surgical removal or alteration of brain tissue responsible for generating epileptic seizures. This procedure is considered when medications fail to adequately control seizures or when the seizure focus is localized and amenable to surgical intervention. Epilepsy surgery aims to improve seizure control, reduce medication burden, and enhance quality of life for patients living with epilepsy. By targeting specific areas of the brain implicated in seizure generation, such as the hippocampus or the temporal lobe, epilepsy surgery offers a potential cure or significant reduction in seizure frequency for eligible candidates, thereby transforming the lives of individuals affected by epilepsy within the Epilepsy Surgery Market.

Epilepsy Surgery Market Size was valued at USD 1.1 billion in 2022. The Epilepsy Surgery market industry is projected to grow from USD 1.16 Billion in 2023 to USD 1.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period (2023 - 2030). 

Segment Analysis

The global epilepsy surgery market has been divided based on procedure type and end user.

Based on procedure type, the market is segregated into resective surgery, laser interstitial thermal therapy (LITT), and others.

Based on end user, the epilepsy surgery market has been divided into hospitals clinics, specialty centers, and others

Regional Analysis

The global epilepsy surgery market has been studied in five regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East Africa. The increasing prevalence of neurological disorders leading to extensive RD on epilepsy treatment devices, increasing cases of brain injuries due to road accidents, and advances in robot-assisted surgery are the common factors driving the growth of the global epilepsy surgery market. According to the WHO, around 50 million people around the globe have epilepsy, making it one of the most common neurological diseases worldwide. It is also estimated that about70% of people living with epilepsy could live seizure-free with the help of proper diagnosis and treatment.

Americas dominated the global epilepsy surgery market owing to various factors, such as the availability of well-established healthcare facilities, the high prevalence of neurological disorders, and the increasing incidence of epilepsy. North America is divided into the US and Canada. With increasing investment in RD, the production of successful epilepsy medications, and a high prevalence of epilepsy, Europe has also evolved as a prominent market for epilepsy surgery.

The Asia-Pacific region offers lucrative opportunities for players in the epilepsy surgery market, owing to the presence of a large geriatric population, governmental initiatives to improve the healthcare sector, an increase in RD activities, and an increase in epilepsy incidence in the region. The Middle East and Africa epilepsy surgery market is segmented into major regions, namely the Middle East, Africa, and Latin America. Factors such as the increasing incidence of epilepsy, the rise in the geriatric population, and the increasing disposable income of people in the region are driving the epilepsy surgery market.

MRFR recognizes the following companies as the top key epilepsy surgery market players —Stryker (US), Zimmer Biomet Holdings Inc.(US),Auris Health, Inc. (Hansen Medical, Inc.) (US), Intuitive Surgical (US),Medtronic Plc (Mazor Robotics) (Ireland), Cephalon, Inc. (US), CMR Surgical(UK), Natus Medical Incorporated(US), Livanova Plc (UK), and Monteris Medical(US).

Key Findings of the Study

• The global epilepsy surgery market is projected to grow from USD 1.16 Billion in 2023 to USD 1.62 billion by 2030 and to register a CAGR of 5.72% during the assessment period.
• The Americas accounted for the largest share of the global market due to the well-developed healthcare sector, rising prevalence and incidence rate of infectious diseases, and the presence of leading players.
• Based on procedure type, resective surgery accounted for a market share of 33.9% in 2020.
• Based on end user, the hospitals clinics segment is expected to register the fastest growth at a CAGR of 6.56% during the forecast period.
• The key market players are Medtronic Plc, Zimmer Biomet Holdings Inc., Stryker, Natus Medical Incorporated, and LivaNova.

For more information visit at MarketResearchFuture